Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 402 participants.

Also called NCT01346865

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 402 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01346865
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01346865. Randomized; double masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2015-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)
Intervention (Drug)
Cilostazol
Intervention (Drug)
Placebo
Lead sponsor
Seung-Jung Park (class: other)
Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01346865
Content hash
63dd3ff8c9fcd6fb86af72a07e8bcad7c9696272aec34c2f49f8e05e4d74be62